These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24636845)

  • 21. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
    Zhou Z; Yang R
    Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
    Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
    Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-CD20 monoclonal antibodies: beyond B-cells.
    Avivi I; Stroopinsky D; Katz T
    Blood Rev; 2013 Sep; 27(5):217-23. PubMed ID: 23953071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia.
    Cooper N; Stasi R; Cunningham-Rundles S; Cesarman E; McFarland JG; Bussel JB
    Br J Haematol; 2012 Aug; 158(4):539-47. PubMed ID: 22775462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B-cell compartment as the selective target for the treatment of immune thrombocytopenias.
    Zaja F; Vianelli N; Sperotto A; De Vita S; Iacona I; Zaccaria A; Masolini P; Tomadini V; Tani M; Molinari AL; Baccarani M; Fanin R
    Haematologica; 2003 May; 88(5):538-46. PubMed ID: 12745273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development.
    Klink DT; van Elburg RM; Schreurs MW; van Well GT
    Clin Dev Immunol; 2008; 2008():271363. PubMed ID: 18596903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab in previously treated primary immune thrombocytopenia patients: evaluation of short- and long-term efficacy and safety.
    Santoro C; Biondo F; Baldacci E; De Propris MS; Guarini A; Paoloni F; Foà R; Mazzucconi MG
    Acta Haematol; 2014; 132(1):24-9. PubMed ID: 24356282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune thrombocytopenia: no longer 'idiopathic'.
    McCrae K
    Cleve Clin J Med; 2011 Jun; 78(6):358-73. PubMed ID: 21632906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orbital B-lymphocyte depletion in a treatment failure of rituximab for thyroid eye disease.
    Gess AJ; Silkiss RZ
    Ophthalmic Plast Reconstr Surg; 2014; 30(1):e11-3. PubMed ID: 23531951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia.
    Audia S; Samson M; Guy J; Janikashvili N; Fraszczak J; Trad M; Ciudad M; Leguy V; Berthier S; Petrella T; Aho-Glélé S; Martin L; Maynadié M; Lorcerie B; Rat P; Cheynel N; Katsanis E; Larmonier N; Bonnotte B
    Blood; 2011 Oct; 118(16):4394-400. PubMed ID: 21876120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab: current status as therapy for malignant and benign hematologic disorders.
    Abdulla NE; Ninan MJ; Markowitz AB
    BioDrugs; 2012 Apr; 26(2):71-82. PubMed ID: 22339395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful treatment of refractory immune thrombocytopenia with rituximab in a 10-week-old infant.
    Gray C; Kalumba K; Pati N; Peterson A; Connell TG
    J Pediatr Hematol Oncol; 2013 May; 35(4):e174-7. PubMed ID: 23459375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
    Roccatello D; Vangelista A; Pani A
    G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
    Kumar S; Benseler SM; Kirby-Allen M; Silverman ED
    Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab in immunologic glomerular diseases.
    Ejaz AA; Asmar A; Alsabbagh MM; Ahsan N
    MAbs; 2012; 4(2):198-207. PubMed ID: 22377738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C; Reu FJ; Ho AD; Hensel M
    Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.
    Moulis G; Lapeyre-Mestre M; Mahévas M; Montastruc JL; Sailler L
    Am J Hematol; 2015 Apr; 90(4):301-5. PubMed ID: 25557586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immune thrombocytopenic purpura: pathophysiology and treatment].
    Godeau B
    Transfus Clin Biol; 2009 May; 16(2):101-5. PubMed ID: 19409827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.
    Latifzadeh SZ; Entezari V
    Clin Appl Thromb Hemost; 2006 Oct; 12(4):489-92. PubMed ID: 17000895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.